PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Not enough new antibiotics in the pipeline, concludes WHO review – especially those targeting deadly drug-resistant microbes

Market faces a catalogue of problems and no ‘silver bullet’ drugs in development to tackle growing antibiotic resistance

2023-03-16
(Press-News.org) **Note: the release below is a special early release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023, Copenhagen, 15-18 April). Please credit the congress if you use this story**

Embargo – 2301H UK time Wednesday 15 March

A review from WHO on the number of new antibiotics currently in the pipeline shows that just 12 new antibiotics have entered the market in the five years from 2017-21.  And there are far too few (just 27) under development in clinical trials against pathogens considered critical* by WHO such as Acinetobacter baumannii and Pseudomonas aeruginosa.  Of these 27, only six are considered ‘innovative’ enough to be capable of overcoming antibiotic resistance using WHO criteria* with only two of those six targeting highly-drug resistant forms of these microbes.

This update on the state of the antibiotic landscape is being presented to a special online session of the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023, Copenhagen, 15-18 April) and is delivered by Dr Valeria Gigante, Team Lead in WHO’s Antimicrobial Resistance Division, Geneva, Switzerland. “In the five years covered by this report, we have had just 12 antibiotics approved, with only one of these – Cefiderocol– able to target all the pathogens deemed critical by WHO,” explains Dr Gigante. “And there are only 27 more currently under development in phase 1 to 3 clinical trials, with little innovation. Only four of the 27 have new mechanisms of action, and most are not new drug classes, but evolution of existing classes.”

Currently, one antibiotic, Solithroymcin - to be used to treat community acquired pneumonia and other infections - is at the ‘new drug application’ stage (passed through clinical trials and awaiting market authorisation) and a further seven products are in phase 3 trials having their efficacy assessed. Dr Gigante explains, that, since failures are possible even in phase 3 trials, it is difficult to predict if and when a market authorisation will be granted for these drugs.

According to recent estimates almost 5 million deaths are already associated each year due to antimicrobial resistance (AMR)[1]. However, the true burden of resistance could be even greater. Furthermore, AMR disproportionately affects poor individuals who have little access to second line, more expensive antibiotics that could work when first-line drugs fail.

Antimicrobials are not as lucrative a prospect as other treatments for pharmaceutical companies, because they are mostly short-term treatments and antibiotic stewardship programs are aimed at conserving or ‘saving’ any such new drugs until they are desperately needed. And they are just as likely to fail during the research and development process as any other drug for other conditions, yet offer a fraction of the revenue returns compared with, for example, cancer and cardiology drugs. As a result of these and other factors, the research and development process for new antibiotics is challenging and poorly funded. The last novel antibiotic class was discovered in the 1980s, and the first antibiotic from this class, daptomycin, reached the market in 2003. 

Resistance to antimicrobials develops because of overuse and improper use, such as people not completing their full course of antibiotics or because of the wrong antibiotic being prescribed – or, in some countries, antibiotics being used widely without prescriptions. The global trend of inappropriate use of antibiotics is demonstrated by the time it takes for resistance to develop to new antibiotics - for antibiotics launched between 1930 and 1950 the average time to develop resistance was 11 years; for antibiotics launched between the 1970 to 2000 it was just 2-3 years.

This silent pandemic of antibiotic resistance continues to grow worldwide. Experts repeatedly warn of a ‘doomsday scenario’ in which routine medical procedures – for example antibiotic prophylaxis in cancer or other disease care – would no longer be effective, and untold numbers of people could die from what were previously simple, treatable infections.

One example of a drug-resistance mechanism experts are worried about is New Delhi metallo-beta-lactamase 1 (NDM-1). Bacteria which contain the gene to produce this enzyme can break down (and are therefore resistant to) a wide-range of carbapenem antibiotics – considered part of the last line of defence in antibiotic treatments where other antimicrobials have failed. The most common bacteria that make this enzyme are Escherichia coli and Klebsiella pneumoniae, but the gene for NDM-1 can spread from one strain of bacteria to another. Prevalence of NDM-1 containing bacteria continues to grow worldwide. Dr Gigante says: “There is a major gap regarding products addressing multi-drug resistant (MDR) pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa (just one agent authorised against all the critical pathogens and few in the pipeline). Very few agents target metallo-β-lactamases, which continue to grow in prevalence. Few new innovative antibiotics are expected in the coming years. We have no silver bullets.”

She adds: “The rapid increase of multidrug-resistant infections worldwide is concerning. Time is running out for us to bring new antibiotics to market and combat this urgent threat to public health. Without immediate action, we risk returning to a pre-antibiotic era where common infections become deadly.”

She concludes: "While we face significant challenges in the fight against antimicrobial resistance, research and development efforts are underway to discover and develop new and hopefully innovative antimicrobial agents, and we have seen promising results in recent years. With increased investment and collaboration across sectors, we can make progress in the fight against antimicrobial resistance and ensure that patients have an equitable and global access to effective treatments for drug-resistant bacterial infections."

In the second presentation at this session, Professor Venkatasubramanian Ramasubramanian, President of the Clinical Infectious Diseases Society of India and Consultant Infectious Diseases & Tropical Medicine, Apollo Hospitals, based in Chennai, India, asks if the current antibiotic pipeline is enough to address the needs of countries with a high burden of drug-resistant infections.

He says: “We have arrived in the post-antibiotic era. The current antibacterial pipeline is woefully insufficient to make a difference in tackling the ongoing threat of antibiotic resistance.”

He will highlight challenges in innovation including the withdrawal of large companies from the antibacterial research space, commercial failures of smaller biotechnology companies, lack of effective policy and regulatory solutions, poor return of investments, cheap generics and fluctuations in waves of infectivity.

He says: “We lack a sustainable economic model for anti-bacterial innovation. To exacerbate the issue, the current products under evaluation mainly cater to the requirements of the developed nations, resulting in a mismatch, especially in developing countries with a high burden of resistance.”

Prof Ramasubramanian will highlight the discrepancy in the priority pathogen list between WHO and the US Centers for Disease Control and Prevention*** He says: “This incongruity is magnified in the list of certain countries like India, who have a high burden of drug resistant organisms. A further twist to the story is when new molecules are developed for resistant organisms, that have shown promise during the developmental stage, fail to perform when strains unique to certain countries are tested. This is due to newer mechanisms of resistance that seem to be continually evolving in high burden countries.”

The talk will conclude with some possible solutions to tackle the current crisis – including the streamlining and fast-tracking of clinical trials assessing new antimicrobials; public-private partnerships across the short, medium and long-term, more investment in basic science research that underpins antibiotic development, and other financial incentives including tax-breaks and better reimbursement models from national health agencies.

Dr Valeria Gigante of WHO’s Antimicrobial Resistance Division, Geneva, Switzerland. Please contact via WHO Press Office. T) +41 22 791 2222 E) mediainquiries@who.int

Professor V Ramasubramanian, President of the Clinical Infectious Diseases Society of India and Consultant Infectious Diseases & Tropical Medicine, Apollo Hospitals, based in Chennai, India. Please e-mail to request interview E) idisdoc@gmail.com

Alternative contact: Tony Kirby in the ECCMID Media Centre. T) +44 7834 385827 E) tony.kirby@tonykirby.com

Notes to editors:

The authors declare no conflicts of interest.

This press release is based on special presentations by Dr Gigante and Prof Ramasubramanian to an online ‘pre-meeting’ of the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

*WHO criteria for ‘innovative’ antimicrobials – must have one of the following features – no cross-resistance, a new target, a new mechanism of action, a new chemical class

**‘critical list’ of bacteria for which new antibiotics are urgently needed: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed

***CDC list of critical pathogens https://www.cdc.gov/drugresistance/biggest-threats.html

WHO factsheet on antibiotic resistance: https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance

 

[1] https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext

END


ELSE PRESS RELEASES FROM THIS DATE:

Short night-time sleep linked with nearly doubled risk of clogged leg arteries

2023-03-16
Sophia Antipolis, 16 March 2023:  Sleeping less than five hours a night is associated with a 74% raised likelihood of developing peripheral artery disease (PAD) compared with seven to eight hours. That’s the finding of a study published today in European Heart Journal – Open, a journal of the ESC.1   “Our study suggests that sleeping for seven to eight hours a night is a good habit for lowering the risk of PAD,” said study author Dr. Shuai Yuan of the Karolinska Institute, Stockholm, ...

New global ranking for life expectancy shows decades-long UK decline

2023-03-16
A new analysis of global rankings of life expectancy over seven decades shows the UK has done worse than all G7 countries except the USA. Researchers writing in the Journal of the Royal Society of Medicine say that while UK life expectancy has increased in absolute terms over recent decades, other, similar countries are experiencing larger increases. In 1952, when Queen Elizabeth II came to the throne, the UK had one of the longest life expectancies in the world, ranking seventh globally behind countries such as Norway, Sweden and Denmark. ...

Humans are altering the diet of Tasmanian devils, which may accelerate their decline

2023-03-16
The Tasmanian devil roams the island state of Australia as the apex predator of the land, feeding on whatever it pleases as the top dog – or the top devil. But some of these marsupial scavengers could be starting to miss out on a few items from the menu. According to a study led by UNSW Sydney, living in human-modified landscapes could be narrowing the diet of the Tasmanian devil. The research, published recently in Scientific Reports, suggests devils have access to vastly different cuisines depending on the type of environment they live in. “We found Tasmanian devil ...

Utah’s graphics pioneers

2023-03-16
They were a group of young, scrappy, but brilliant University of Utah computer science students and professors who changed the world. Ed Catmull. John Warnock. Jim Clark. Alan Kay. Ivan Sutherland. Martin Newell. They are a just a handful of the luminaries in the late 1960s and 1970s who revolutionized computer graphics by inventing technologies that have aided and shaped countless industries today. For the first time ever, these and other legends of that time will be reuniting on the U campus Thursday, March 23, and Friday March 24, to commemorate their roles as ...

Humans are not just big mice: Study identifies science’s muscle-scaling problem

2023-03-16
CHICAGO — March 16, 2023 — In science, findings generated from studying small animals often are generalized and applied to humans, which are orders of magnitude larger. New research, which was led by Shirley Ryan AbilityLab and will be published in a forthcoming issue of the Journal of Physiology, not only is the first to directly measure human muscle contractile properties; it also is the first to show that extrapolating such information to humans based on animal measurements generates incorrect predictions. The discovery occurred initially when researchers leveraged a unique surgical technique in which a human patient’s ...

U.S. opioid crisis best viewed as a connected ecosystem

2023-03-16
The nation’s opioid crisis, which kills thousands of Americans annually, is best viewed as an ecosystem where all parts of the vexing problem are interconnected, underscoring the need for holistic solutions that address the broad needs of those battling addiction, their families and the communities where they live, according to a new report from the nonprofit RAND Corporation.   Too often different actors in the ecosystem focus primarily on addressing just one part of the problem, with each component of the system having its own priorities and initiatives ...

Trust in cancer information declined among Black Americans during the pandemic

2023-03-16
Trust in information given out by the government on cancer fell sharply among the Black population, by almost half, during the COVID-19 pandemic findings of a national US study have shown.  Experts are warning the vital need to monitor if this mistrust has persisted beyond the pandemic and whether it could potentially cause an upsurge in late or fatal diagnoses – following a lack of uptake of important cancer prevention measures such as routine screening and human papilloma virus (HPV) vaccinations.   The findings, published today in the peer-reviewed ...

OMG, texting intervention prevents teen pregnancy among lesbian and bisexual girls

2023-03-16
A new texting intervention that University of British Columbia researchers helped develop is more effective at promoting healthy sexual decision-making and reducing pregnancies among sexual minority teens than most existing interventions in the U.S. Girl2Girl, developed and tested by the Center for Innovative Public Health Research (CIPHR) in San Clemente, Calif., in partnership with UBC’s Stigma and Resilience Among Vulnerable Youth Centre, is the first texting-based intervention specifically aimed at lesbian and bisexual teens. “For more than 30 years, research ...

Employees tend to avoid taking breaks despite high levels of stress

2023-03-16
Heavy workloads make employees feel a greater need for a break, but new research finds they may actually discourage employees from taking breaks at work despite causing high levels of stress, fatigue, and poor performance. Researchers from the University of Waterloo found employees often kept working despite wanting to pause. One potential reason is employees may have felt pressure to continue working to get everything done on time.  “Our research provides a comprehensive account of the processes involved in the decision to take a break and provides insights into how employees and managers can make more effective use of breaks at work, ...

Aging | AAV1.NT-3 gene therapy prevents age-related sarcopenia

Aging | AAV1.NT-3 gene therapy prevents age-related sarcopenia
2023-03-15
“Considering the cost and quality of life to the individual, we believe our study has important implications for management of age-related sarcopenia.” BUFFALO, NY- March 15, 2023 – A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 5, entitled, “AAV1.NT-3 gene therapy prevents age-related sarcopenia.” Sarcopenia is progressive loss of muscle mass and strength occurring during normal aging with significant consequences on the quality of life for elderly. Neurotrophin 3 (NT-3) is an important autocrine factor supporting ...

LAST 30 PRESS RELEASES:

Unveiling the mysteries of cell division in embryos with timelapse photography

Survey finds loneliness epidemic runs deep among parents

Researchers develop high-energy-density aqueous battery based on halogen multi-electron transfer

Towards sustainable food systems: global initiatives and innovations

Coral identified as oldest bioluminescent organism, suggesting a new model of ancient ecology

SRI chosen by DARPA to develop next-generation computational design of metallic parts and intelligent testing of alloys

NJIT engineers muffle invading pathogens with a 'molecular mask'

Perinatal transmission of HIV can lead to cognitive deficits

The consumption of certain food additive emulsifiers could be associated with the risk of developing type 2 diabetes

New cancer research made possible as Surrey scientists study lipids cell by cell 

Bioluminescence first evolved in animals at least 540 million years ago

Squids’ birthday influences mating

Star bars show Universe’s early galaxies evolved much faster than previously thought

Critical minerals recovery from electronic waste

The move by Apple Memories to block potentially upsetting content illustrates Big Tech’s reach and limits, writes Chrys Vilvang

Chemical tool illuminates pathways used by dopamine, opioids and other neuronal signals

Asian monsoon lofts ozone-depleting substances to stratosphere

PET scans reveal ‘smoldering’ inflammation in patients with multiple sclerosis

Genetics predict type 2 diabetes risk and disparities in childhood cancer survivors

Health information on TikTok: The good, the bad and the ugly

New study points to racial and social barriers that block treatment for multiple myeloma

Rensselaer researcher finds that frog species evolved rapidly in response to road salts

A new chapter in quantum vortices: Customizing electron vortex beams

Don’t be a stranger – study finds rekindling old friendships as scary as making new ones

There’s no ‘one size fits all’ when it comes to addressing men’s health issues globally

Comparison of the “late catch-up” phenomenon between BuMA Supreme and XIENCE stents through serial optical coherence tomography at 1–2 month and 2 year follow-ups: A multicenter study

Marine plankton communities changed long before extinctions

Research reveals tools to make STEM degrees more affordable

Q&A: UW research shows neural connection between learning a second language and learning to code

Keane wins 2024 Gopal K. Shenoy Excellence in Beamline Science Award

[Press-News.org] Not enough new antibiotics in the pipeline, concludes WHO review – especially those targeting deadly drug-resistant microbes
Market faces a catalogue of problems and no ‘silver bullet’ drugs in development to tackle growing antibiotic resistance